| Oregon Health and Science University Patent applications |
| Patent application number | Title | Published |
|---|
| 20110213278 | MOVEMENT MONITORING SYSTEM AND APPARATUS FOR OBJECTIVE ASSESSMENT OF MOVEMENT DISORDERS - Disclosed embodiments include a movement monitoring system and apparatus for objective assessment of movement disorders of a subject, comprising (a) one or more movement monitors, and (b) a computer-implemented analysis system comprising one or more protocols and associated data analysis methods to objectively quantify movement disorders based on movement data acquired by the movement monitors. According to one embodiment, the movement monitors are robust wireless synchronized movement monitors and the protocols include one or more tests for assessment of neural control of balance. | 09-01-2011 |
| 20110213277 | SYSTEM, METHOD, AND APPARATUS FOR OBJECTIVE ASSESSMENT OF MOTOR SIGNS AT THE EXTREMITIES - Disclosed embodiments include a system for objective assessment of motor signs at the extremities that comprises (a) a device for objective motor sign measurement, (b) a test protocol defining a prescribed repetitive activity, and (c) a signal processing and analysis system to generate one or more impairment metrics. According to a particular embodiment, the device for objective motor sign measurement is characterized by including means for producing a continuous measure of position of a limb or extremity during said prescribed repetitive activity during the entire movement. | 09-01-2011 |
| 20090209461 | MODIFICATION OF FEEDING BEHAVIOR - Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject. | 08-20-2009 |
| 20090104163 | Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 04-23-2009 |
| 20090062844 | SPIDER PFO CLOSURE DEVICE - A device for occluding septal defects or other bodily passageways including PFOs, includes an occluding body formed from a plurality of flexible outwardly radiating occluding wires connected to one or more biocompatible sheet materials. The occluding wires are joined together at proximal wire ends. Linking members connectively link the occluding body to a flexible, substantially linear anchor formed from at least one tube, coil, or bar. The anchor is configured for placement on one side of bodily passageway, whereby the longitudinal axis of at least one anchor extends across a transverse cross-section of the bodily passageway, anchoring the occluding body in place against the other side of a bodily passageway to close, occlude, or fill at least a lumenal portion of a bodily passageway. The anchor may include one or more grasping member(s) integrally formed or connected to the tube, coil, or bar for releasable attachment to an anchor engaging member, such as a biopsy forceps. In a further aspect, a closure device assembly includes a delivery catheter housing a collapsibly disposed closure device linked to a biopsy forceps. The biopsy forceps may be positioned in a locking catheter, which is configured to prevent inadvertent release of the closure device when held in a compressed state inside the delivery catheter. By positioning the catheter near a bodily passageway, such as a PFO, and disengaging the anchor engaging member from the grasping member, the closure device may be released so as to facilitate stable closure of the bodily passageway. | 03-05-2009 |
| 20080318236 | Cell Free Screening Assay and Methods of Use - Methods are disclosed for identifying agents for the treatment of cancer and/or Fanconi anemia using | 12-25-2008 |
| 20080214609 | Development of new selective estrogen receptor modulators - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions. | 09-04-2008 |
| 20080206231 | Compositions and Methods for Treating Disease - The present invention discloses for the first time that the insulin receptor (IR) is a target of Herstatin, which modulates IR and IR-mediated intracellular signaling. In preferred aspects, Herstatin binds at nM concentrations to cell-surface IR, up-regulates basal IR expression by several-fold, induces the accumulation of pro-IR, and stimulates insulin activation of the ERK pathway. Moreover, these changes in insulin signaling are accompanied by alterations in IGF-IR expression, IRS-2 levels, and the serine phosphorylation state of both IRS-1 and IRS-2. Preferred aspects provide novel therapeutic methods and pharmaceutical compositions for treatment of conditions associated with altered IR expression or IR-mediated signaling, including but not limited to insulin resistance syndrome, pre-diabetic conditions, metabolic syndrome, type 1 and type 2 diabetes, cardiac disease, diabetes-associated vascular disease, atherosclerosis, hypertension, diabetes-associated lipid metabolism disorders (dyslipidemia), obesity, critical illness, neurodegenerative disorders, and combinations thereof, and cancer. | 08-28-2008 |
